Soleno Therapeutics (SLNO) Shares Outstanding (Weighted Average) (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $52.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $52.1 million, up 12.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.1 million (up 12.8% YoY), and the FY2025 annual result was $251599.0, down 99.37% from the prior year.
• Shares Outstanding (Weighted Average) improved to $52.1 million in Q1 2026 per SLNO's latest filing, from $251599.0 in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $52.1 million in Q1 2026 and troughed at $251599.0 in Q4 2025.
• A 5-year average of $25.0 million and a median of $16.5 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) surged 24423.49% in 2022, then tumbled 99.37% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $8.4 million in 2022, then soared by 96.4% to $16.5 million in 2023, then surged by 143.61% to $40.2 million in 2024, then plunged by 99.37% to $251599.0 in 2025, then surged by 20604.0% to $52.1 million in 2026.
• Business Quant data shows SLNO's Shares Outstanding (Weighted Average) at $52.1 million in Q1 2026, $251599.0 in Q4 2025, and $50.0 million in Q3 2025.